Clinical trials: CDA
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia.
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- Trial name
- NCT02115295
- Testing
- Cladribine, Cytarabine, Gilteritinib
- Where
- United States
- Volunteers
- 508 people
- Sponsor
- M.D. Anderson Cancer Center
Peripheral Artery Disease
Telehealth to Improve Functional Status and Quality of Life in Veterans With PAD
The present study aims to increase Veteran access to supervised exercise therapy and expand its role in improving functional status, quality of life, and cardiovascular risk profile of Veterans with PAD.
- Trial name
- MOVE-IT (NCT05048979)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Relapsing-Remitting
Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the central nervous system. Typical brain lesions of the disease may be partially repaired by an endogenous remyelination process which is limited…
- Trial name
- CLAREMI (NCT05902429)
- Testing
- Cladribine 10 mg oral tablet
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidade Católica do Rio Grande do Sul
Leukemia, Myeloid, Acute
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
This study will evaluate the investigational drug Midostaurin in various doses given with ATRA and CLAG chemotherapy. Midostaurin is a FLT3 inhibitor that is activated or overexpressed in a significant proportion of AML patients.
- Trial name
- CLAG ATRA AML (NCT01161550)
- Testing
- Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Relapsing-Remitting Multiple Sclerosis
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
- Trial name
- NCT04997148
- Where
- 8 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
This phase I/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leukemia (cHCL) that has come back after a period of improvement…
- Conditions
- Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia
- Trial name
- NCT06965114
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation
For acute leukemia patients with early relapse after allogeneic stem cell transplantation, the overall outcome is poor. In this study, we evaluate the treatment outcome and safety of chemotherapy with Cladribine, cytarabine and…
- Trial name
- NCT02910752
- Testing
- CLAM+PBSC
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Malaria, Falciparum
Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi
Sulfadoxine-pyrimethamine is the current first-line therapy for uncomplicated malaria in Malawi. Significant resistance of the P.
- Trial name
- NCT00164359
- Testing
- Amodiaquine plus artesunate, chlorproguanil-dapsone plus artesunate
- Where
- 3 sites in Malawi
- Volunteers
- 212 people
- Sponsor
- Centers for Disease Control and Prevention
Caregivers
Pilot Study of Hospital GamePlan4Care
Hospital stays are stressful for the family and friends who care for adults with dementia. Following hospital discharge, adults with dementia often have increased care needs, which places new caregiving demands on their family…
- Trial name
- NCT06634368
- Testing
- Hospital GamePlan4Care, Health Education
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- VA Office of Research and Development
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
the Efficacy and Safety of CLAE in R/R T-ALL/LBL
To evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL.
- Trial name
- NCT04679506
- Testing
- Cladribine
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Acute Myeloid Leukemia, Relapse Leukemia
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
The vast majority of patients with AML will die of the disease, and no standard chemotherapy regimen were defined for patients with relapsed/refractory AML.
- Trial name
- NCT03181815
- Testing
- Cladribine, G-CSF, Aclarubicin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Congenital Dyserythropoietic Anemia (CDA)
The Congenital Dyserythropoietic Anemia Registry (CDAR)
The investigators have created and maintain a comprehensive registry for patients with the diagnosis of Congenital Dyserythropoietic Anemia (CDA) in North America.
- Trial name
- NCT02964494
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Systemic Mastocytosis
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with advanced systemic mastocytosis carrying D816V or…
- Trial name
- NCT01602939
- Testing
- Cladribine and pegylated interpheron alpha-2a
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Virgen de la Salud
Cigarette Use, Alcohol Use Above Recommended Limits
Developing a Team-Delivered Intervention for Smoking and Hazardous Drinking for Primary Care Veterans With Cardiovascular Diseases
In this study, the investigators are interested in learning how patients feel about and are impacted by a new approach for the primary care team to use to talk to patients about heart disease and health behaviors.
- Conditions
- Cigarette Use, Alcohol Use Above Recommended Limits, Cardiovascular Risk Factors (e.g., Hypertension), Cardiovascular Diseases
- Trial name
- CARE (NCT05275582)
- Testing
- CARE
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Depression
Improving Depression Management
Depression is disabling and affects one in five Veterans. VA's Primary Care-Mental health Integration (PC-MHI) enables specialists to support medication treatment in primary care, but timely and sufficient access to psychotherapy…
- Trial name
- IDMPC (NCT05050227)
- Testing
- cCBT Enhanced Collaborative Care, Usual Care
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- VA Office of Research and Development
Acute Myeloid Leukemia
Cladribine Venetoclax in Monocytic AML
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
- Trial name
- NCT06232655
- Testing
- Cladribine, Venetoclax, Azacitidine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other…
- Trial name
- NCT05797740
- Testing
- Mavenclad
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 366 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
PTSD
Shared Decision Making for PTSD in Primary Care
PTSD is one of the most common mental health conditions affecting Veterans and is associated with significant burden. Highly effective treatments exist for PTSD, evidence-based psychotherapies, but very few Veterans receive them.
- Trial name
- PRIMED-PTSD (NCT04504149)
- Testing
- Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD
- Where
- United States
- Sponsor
- VA Office of Research and Development
Refractory Acute Leukemia, Relapsed Acute Leukemia
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
To find the recommended dose of the drug combination cladribine, cytarabine, decitabine, and sorafenib in participants with relapsed/refractory AML, MPAL, and ALAL.
- Trial name
- NCT06474663
- Testing
- Cladribine, Cytarabine, Sorafenib
- Sponsor
- M.D. Anderson Cancer Center
Tobacco Use
Tobacco Cessation Treatment Preferences Among Veteran Smokers
There are significant barriers to tobacco cessation treatment for patients and providers in specialty care clinical settings. Specialty providers cite several barriers to delivering evidence-based tobacco cessation care…
- Trial name
- MESH (NCT05277207)
- Testing
- Personalized Smoking Cessation Facilitation Meetings, Personalized Smoking Cessation Pharmacotherapy, Personalized Text Messaging Support
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development